Evaluating Product Characteristics for Acceptance Mark D. Johnson, PMP ASQ CMQ/OE & CQE AbbVie Inc.
-
Upload
alexis-cross -
Category
Documents
-
view
221 -
download
2
Transcript of Evaluating Product Characteristics for Acceptance Mark D. Johnson, PMP ASQ CMQ/OE & CQE AbbVie Inc.
Evaluating Product Characteristics for Acceptance
Mark D. Johnson, PMPASQ CMQ/OE & CQE
AbbVie Inc.
Midwest Biopharmaceutical Statistics Workshop
2
Agenda
• Product Characteristics• Defect Rating Criteria• Sampling Techniques• Questions
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
3
Product Characteristics
• Identify characteristics important to confirming product performance
• These might be items such as:Component dimensions for device componentsContent uniformity for tabletsPotency and impurities for a drug product lotForce to activate an autoinjectorCorrect tablet coloring for different dosage
strengths of same product
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
4
Product Characteristics
Product characteristics can be based on:• Compendial performance expectations• Current quality attribute testing for a similar
product• New tests required to assess unique features of a
new product• Product features designed to address specific user
needs
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
5
Defect Rating CriteriaWhen a pharmaceutical, medical device or combination product is defective, three defect types are possible:
• Design - the pharmaceutical was manufactured correctly, but anticipated or unanticipated side effects caused by the drug use resulted in patient harm or injury; the medical device was poorly designed or not properly tested, creating a situation where the products might be defective and dangerous.
• Manufacturing - the product was designed to meet requirements, but manufactured improperly or contaminated somehow during the manufacturing process, potentially exposing the patient to harm.
• Marketing – the product’s instructions, warnings, or recommendations for the use of the drug are not sufficiently clear or appropriate to help consumers use the product correctly.
Reference: HG.org Legal Resources Website
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
6
Defect Rating CriteriaExamples of the three defect types are:
• Design – An infusion pump screen design is cumbersome or confusing to users, which causes a delay in therapy. For example, the “Start Infusion” key may be located next to the “Power” key, and a user may turn off the infusion pump and lose programmed pump settings instead of initiating infusion. In some cases, programmed settings are lost when a user turns the pump off, and the infusion settings have to be re-entered after the pump restarts.
• Manufacturing – Excess water has entered a drug substance batch manufacturing run, due to a faulty valve in the purified water system. This resulted in elevated impurity and reduced potency levels within the batch.
• Marketing – A patient does not adequately comprehend the medication’s use instructions that require him to eat a meal and drink water prior to taking his daily dose.
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
7
Defect Rating Criteria• Product characteristics need to be examined to determine the
impact of not meeting their acceptance criteria• These characteristics might be based on similar attributes
assessed for a comparable product• Likewise, they may be identified and confirmed during the
Process Validation Lifecycle activities recommended to document development, verification, validation and future manufacture of the product
• This examination may be based on evaluating the impact of the defect upon product functionality or clinical effect to a user
• Also, risk-based evaluation can be used to identify the impact of a product defect
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
8
Defect Rating Criteria• Product sampling based on identification of defects was initially
used in the Aerospace industry• This approach was adopted within the pharmaceutical industry in
the 1970s and 1980s• There is no industry-wide consensus on a specific percent defective
level used to characterize Critical, Major, Minor or Cosmetic defects• Dr. Wayne Taylor, a recognized sampling expert, cited the following
percent defective levels were commonly used to assess medical devices for product defects:Critical (Health and Safety): 0.065%, 0.1%, 0.25% Major (Functional): 0.25%, 0.4%, 0.65%, 1.0%Cosmetic: 2.5%, 4.0%
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
9
Defect Rating CriteriaProduct Attribute Typical Assigned AQLsCritical 0.04%, 0.065%, 0.1%, 0.15%, 0.25%Major Functional 0.25%, 0.4%, 0.65%, 1.0%Minor Functional 0.65%, 1.0%, 1.5%Cosmetic Visual 1.5%, 2.5%, 4%, 6.5%
• Acceptance Quality Limits (AQLs) in Pharma / Devices• These attribute categories help identify the foci of our sampling activities.• Are we only interested in assessing superficial product characteristics, or do
we need to assess critical product operations or functions as well?• We use these attribute categories to assure our processes operate to meet or
surpass our expectations for observing defective product.
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
10
Defect Rating Criteria
Defect rating criteria may be defined as:• Critical: A nonconformity likely to present a hazard to
health • Major Functional: A nonconformity which may cause the
product to be unfit for use, significantly degrades its function or performance, or is likely to generate a complaint
• Minor Functional: A nonconformity which may cause the product to function poorly or a user inconvenience, but may still be fit for use, or possibly generate a complaint
• Cosmetic Visual: A nonconformity detrimental to the high quality image of a product that will not affect usability or functionality, but affects only appearance of the product
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
11
Defect Rating Criteria
These criteria can be based on:• Similar defects experienced with a similar product• Historically observed defects for the product’s dose
modality (e.g., oral solution, tablets, capsules)• Risk-based assessment of hazardous situations/failure
modes experienced with the product• Means of evaluating product performance vs. current
test methods or other necessary standards
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
12
Defect Rating Criteria
Assessment of these criteria is completed by:• Laboratory testing of product vs. required quality
attributes• Functional testing of product to meet operational
requirements• Visual examination for any noticeable defects
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
13
Sampling Techniques
• To assess product characteristics, an adequate sample of sufficient confidence must be used
• Based on the defect level of the characteristic of interest, different confidence levels might be considered for validation purposes:Critical (e.g., % defective ≤ 0.4%), validate to ≥ 90%
confidenceMajor (e.g., 0.40% < % defective ≤ 2.5%), validate to ≥ 50%
confidenceMinor (e.g., % defective > 2.5%) validate to ≥ 20%
confidence
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
14
Sampling Techniques
Similarly for process validation activities, an adequate level of confidence is also required:• New process/product or major process change,
validate to ≥ 90% confidence• Routine revalidation, validate to ≥ 50% confidence• Minor process change or accelerated testing,
validate to 20-50% confidence
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
15
Sampling Techniques
There are different methods available to sample product for inspection: • Simple Random Sampling – Selecting samples so that each
unit has an equal chance of being selected• Stratified Random Sampling – Selecting samples
deliberately from each time period or location in a batch• Nested Sampling – Selecting units from locations within a
batch and obtaining multiple samples from each location• Systematic sampling – Selecting units periodically over time
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
16
Sampling Techniques
6.04.02.00.40.0
1.0
0.8
0.5
0.1
0.0
n sample sizec acceptance number
Lot Percent Defective
Prob
abili
ty o
f Acc
epta
nce
55 0175 0575 0
n c
Operating Characteristic (OC) Curve, 0.4% Defective Sampling Plans
Plan Confidence = (1-Probability of Acceptance)*100%
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
17
Sampling TechniquesValidation vs. Product Acceptance Sampling Plans – What are the differences?• Validation Sampling
Cannot assume process is good, because it has not been validated yet Need to prove it's good "Guilty until proven innocent“ Need to use tighter sampling plan than one used for product acceptance (e.g., will reject
when data shows high confidence (e.g., 90% or 95%) that product performance vs. acceptance criteria is worse than acceptable % defective)
• Product Acceptance Sampling Assumes process is good, since process successfully validated "Innocent until proven guilty“ Will only reject when data shows low confidence (e.g., 5-10%) product performance vs.
acceptance criteria is worse than the AQL
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
18
Sampling Techniques
If you pass the “n=575, a=0” PPQ sampling plan, you have 90% confidence (e.g., (1-0.1 Pr(Accept)*100%) you will accept a lot ≤ 0.4% Defective.
If you pass the “n=32, a=0” Product Acceptance sampling plan, you have 12% confidence (e.g., (1-0.88 Pr(Accept)*100%) you will accept a lot ≤ 0.4% Defective.
10.08.06.04.02.00.40.0
0.95
0.50
0.10
0.00
n sample sizec acceptance number
% Defective
Pr(A
ccep
t)
575 032 0
n c
Operating Characteristic (OC) Curve0.4% Validation Sampling (Blue) vs. Product Acceptance Sampling (Red)
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
19
Sampling Techniques
• Once the process has been validated, the confidence of the sampling plan can be relaxed to routinely assess batches for large quality defects.
• ANSI Z1.4 provides attribute sampling plans to be used for routine lot inspection and acceptance
• ANSI Z1.9 provides variables sampling plans to be used for routine lot inspection and acceptance
• Both plans provide switching rules for transitioning from normal to tightened, tightened to normal, normal to reduced and reduced to normal sampling practices, dependent on the continuing documented quality history of the product
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
20
Sampling Techniques
• Once you’ve determined the product characteristics to assess vs. their required acceptance criteria, you can build a sampling approach
• Two types of sampling plan approaches typically used:Attributes: units assessed within each sample can only
pass or fail the acceptance criteriaVariables: mean and standard deviation are calculated
for a sample of units, then a range is calculated using a factor suitable to the defect level and sample size for comparison with the acceptance criteria
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
21
Sampling Techniques
• Attribute characteristic examples:Fill volume: >20 mLTablet defects: cracked, chippedExtraneous matter: visible particulate, rubber, hair
• Variables characteristic examples:Component dimensions: Length = 2 ± 0.25 mmEjection force: ≤ 10 NewtonsCrush test for tablet: ≥ 100 Newtons
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
22
Sampling Techniques
• Attribute Sampling:Easy to conclude result, either pass/failMany samples might be required to provide adequate
confidence in pass/fail decision• Variables Sampling:
Variables data contains more information than percent nonconforming
More descriptiveMore statistical information and powerFewer samples required for same statistical power
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
23
Sampling Techniques
8.06.04.02.00.40.0
0.95
0.50
0.20
0.10
0.00
Lot Percent Defective
Pro
bability
of A
ccepta
nce
n sample sizec acceptance number
90% conf 575 050% conf 175 020% conf 55 0Tightened 50 0Normal 32 0
n c
Operating Characteristic (OC) Curve0.4% Defective Attribute Sampling Plans
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
24
Sampling Techniques
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
25
Questions…
20 May 2015
Midwest Biopharmaceutical Statistics Workshop
26
Thank You!
20 May 2015